New drug trial aims to stop Body's attack after Life-Saving transplants

This study is testing if adding a new drug called itacitinib to standard treatment can prevent a serious complication called graft-versus-host disease (GVHD) in patients who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor's immune cells attack the patient's body. The trial involves 31 adults and compares their outcomes to matched patients who received standard care alone to see if the new combination is more effective.